BCM
SCLN

BlueCrest Capital Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

BlueCrest Capital Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-28,981
Closed -$201K – 1290
2015
Q3 		$201K Sell
28,981
-34,019
-54% -$291K 0.01% 803
2015
Q2 		$619K Buy
+63,000
New +$574K 0.02% 583

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlueCrest Capital Management's SCLN Position: Q4 2015 in Review

BlueCrest Capital Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2015, closing a stake of 28,981 shares — an estimated $201K sold.

BlueCrest Capital Management first reported a position in SCLN in Q2 2015 and held it in 2 quarters. The position peaked at $619K in Q2 2015. 133 funds tracked by Wall St. Rank hold SCLN as of Q4 2015.

  • BlueCrest Capital Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2015 after selling out during the quarter.
  • BlueCrest Capital Management sold 28,981 Sciclone Pharmaceuticals Inc shares in Q4 2015, an estimated $201K.
  • BlueCrest Capital Management first reported a position in Sciclone Pharmaceuticals Inc in Q2 2015 and held it in 2 quarters.
  • BlueCrest Capital Management's Sciclone Pharmaceuticals Inc position peaked at $619K in Q2 2015.
  • 133 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2015.

Based on BlueCrest Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.